Bayer (China)

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

Hepatology, Medicine, Cancer Management +12

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial

Riccardo Lencioni, Josep M. Llovet, Guohong Han et al. · Journal of Hepatology · 2016 · 680 citations · Full text

Doxorubicin-eluting Beads, Intermediate Stage Hcc, Pharmacology +8

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Rury R. Holman, Ruth L. Coleman, Juliana C.N. Chan et al. · The Lancet Diabetes & Endocrinology · 2017 · 316 citations

Metabolic Syndrome, Glucose Tolerance, Diabetes Management +10

Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study

Steven D. Nathan, Jürgen Behr, Harold R. Collard et al. · The Lancet Respiratory Medicine · 2019 · 228 citations

Hypertension, Pulmonary Arterial Hypertension, Placebo-controlled Phase 2B +6

Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization

Yasushi Ikuno, Kyoko Ohno‐Matsui, Tien Yin Wong et al. · Ophthalmology · 2015 · 209 citations

Ocular Disease, Intravitreal Aflibercept Injection, Ophthalmology +2